Rod Wong
Founder & Managing Partner, RTW Investments · 1 appearance on the record.
computed by AI from the episodes · how this works → · full disclaimer →
investorfounderexecutiveacademicLinkedIn ↗rtwfunds.com ↗
Roderick (Rod) Wong is an MD/MBA-trained life sciences investor who founded RTW Investments, focused on company creation, biotechnology, and medtech. Beyond investing, he established the RTW Foundation to support rare disease research and has taught healthcare financial analysis as an adjunct professor at NYU Stern.
35statements → 7claims → 2claims resolved → 3.63/5average certainty → 2.06/5average debate potential → ≈4.5/5argument clarity, estimated →
1 supported 0 partly supported 1 contradicted 5 not checkable as stated how the 7 claims stand · each chip opens the sources
3 predictions · 4 assertions · 5 opinions · 17 insights · 6 disclosures · every statement was checked. The predictions and assertions are the 7 claims: statements the public record can support or contradict. 2 are resolved, and 5 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.
The record, in short
What the tape says about how Rod argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.
Their most notable supported claim
Wong: Biotech is in its second-deepest and second-longest bear market ever
“So we are 18 months into a biotech bear market that's the second worst
Correction in the history of the industry, right?
The first being the obvious one, the genomics bubble bursting in 2000 to 2003.
It's second longest, second deepest.”
Their most notable contradicted claim
Expressed certainty vs assessment result
weighted support: a fully supported claim counts one, a partly supported claim counts half. Each filled bar is clickable and opens exactly those claims; "none yet" means nothing said at that certainty level has resolved yet
How they sound: not measured why? →
We measure speaking style by listening to the audio itself, and a fair number needs at least 2,000 words from one person on tape we have measured. There is too little of Rod Wong on measured tape to publish a rate. This says nothing about how they speak.
Everything Rod Wong said on Capital Allocators that made the record, most notable first. Filter by type, assessment or year in the ledger →
Wong: Doubling drug approvals to 80 will drive massive biotech value creation
“On average, we've been approving forty-ish drugs a year, and if 40 goes to 80, even if you're losing some on pricing, it should be a tremendous amount of value creation.”
Wong: Long-term biotech investing struggles within non-specialized firms
“I mean, honestly, I think biotech, especially the way we, that I've always done it, which is longer term oriented, is difficult to fit in any larger firm that's not focused only on healthcare.”
Rod Wong: Healthcare portfolios should be concentrated because mispriced drugs are scarce
“So at the end of the day, the strategy was find those things that offer high probability asymmetric risk reward over a medium to long duration and build a portfolio out of those things, recognizing that great drugs that are underappreciated by the market shoul…”
Wong: Most asset management firms rely on lone wolf culture
“Most asset management firms, even very, very successful people, even big firms are structured as very small teams, sometimes just flat out individuals. There's a lot of lone wolf Culture.”
Wong: Academic lab cultures foster egos that complicate cross-functional management
“They are small teams that are very, very good at what they do. And you develop big personalities, big egos from that. And that's a management challenge when what you're talking about is you want people with different expertise to really come together and work …”
Wong: Biotech positions above 5% require commercial revenue support
“So we'll have larger positions that are five to 10% plus of the portfolio. That must mean that those larger positions have some kind of base business value support. They sell a drug on the market, and we're playing for the second drug. And then you have a numb…”
Wong: Strong Phase 2 p-values in constipation drugs repeatedly failed Phase 3
“We studied all these historical constipation trials, going back into the literature, and we found that phase twos, a lot of them work, and phase threes, they all fail, every single one. So empirically, we said, actually, the statistician is wrong. Doesn't matt…”
Wong: Biotechs launching sub-billion-dollar drugs face severe commercial funding challenges
“One particular example that we find kind of interesting is that companies that actually have succeeded all the way, you know, through development, and they're getting ready to launch a product, but that product is a sub one billion dollar peak sales product. C…”
Wong: Biotech needs optimization of existing modalities, not new ones
“And I actually think that we don't need to increase the number of modalities at all. If we just focused on improving what we have, this new updated list, I think that would last the industry 10 to 20 years.”
Rod Wong: FDA staff turnover is driving more conservative regulatory decisions
“COVID actually had a major impact on how the FDA functions. They moved heaven and earth to get those vaccines and the first handful of drugs approved. It burned a lot of people out. And so you had tremendous turnover at FDA and there's a whole training process…”
Wong: Biotech is in its second-deepest and second-longest bear market ever
“So we are 18 months into a biotech bear market that's the second worst
Correction in the history of the industry, right?
The first being the obvious one, the genomics bubble bursting in 2000 to 2003.
It's second longest, second deepest.”
Wong: Biotech has more than tripled its mature drug production modalities
“We've more than tripled the number of technologies
That you can produce drugs from, and that list I just kind of rattled off, that's not science fiction.
The only things I've named are things that have proven themselves mature enough to actually have drugs com…”
Wong: Biotech innovation boom will drive drug development for decades
“I think it's those two factors that are driving the boom, and I think, you know, it should be a couple decades at least of then improving these modalities, utilizing the information, and just getting a lot more drugs developed.”
Wong: Drug development enjoys relatively strong value capture via pricing
“Drug development is one of the sectors that has relatively good value capture via pricing.”
Wong: Biotech multi-baggers require multi-stage support over roughly five years
“When you think about what actually drives the business or the returns of the funds, it is finding things early when they're misunderstood or simply no one's paying attention, doing the work, getting convicted, and then supporting it along multiple steps, stage…”
Wong: RTW applies value investing frameworks to binary biotech development
“We're fundamentally value oriented and we are looking for asymmetric risk reward. The trick is that you have to overlay that we live in a probabilistic business or one that's binary.”
Wong: Extreme outliers in biotech management quality are exceedingly rare
“I put things in three basic buckets. Low percentage of the time management that is so stellar. That you think they can take a very marginal product, right? They can sell ice to an Eskimo, and there's drugs like that. And they can find a way to get it across th…”
Wong: Position sizing requires continual re-underwriting of catalyst probabilities
“We just consider each point in time, almost kind of like you're re-underwriting the investment, right? So No matter where an investment is trading or where it's been marked last, you're thinking about then what is the next step in terms of key event, probabili…”
Wong: In Q2 2022 biotech stocks sold off even on positive news
“You know, as an example kind of the worst part of the bear market sell-off, this cycle, Q-two of last year, you could have been right on everything, right? Call the event right, Day the news comes out, the stock trades down because it's a source of liquidity l…”
Wong: RTW limits worst-case position loss to 5% of fund capital
“Our best ideas, this conviction piece, our very best ideas. And sometimes we don't even have one that reaches this level in a given year, but we are willing to take up to a five percent loss if we're flat out wrong.”
Wong: Strategic blockbuster biotechs command strong valuations despite market downturns
“So I would say those biotech companies, so the, of the targets the ones that are, that have the best seat in the house are the ones that are developing drugs that have the potential to move the needle for a pharma. So it has to be a blockbuster drug and is in …”
Wong: UK listed funds suffer from illiquidity and a shallow investor base
“I think the challenge is that UK in general, and then specifically for listed funds, there's not a deep audience and there's not a lot of liquidity for that.”
Wong: Around a dozen dedicated healthcare firms manage over $1B
“I don't know the exact number, but healthcare dedicated firms that are managing meaningful amounts of capital, like north of a billion dollars is probably, you know, a dozen plus or minus something like that.”
Wong: Healthcare investment culture defaults to collaboration over competition
“The culture that developed in our ecosystem was one that we worked together to get things. So most of us are friends with some portion of the rest of us. And the culture is to default to not be competitive, but try to be collaborative. And that spirit, I think…”
Appearances (1)
| Episode | Date | Speaking time |
|---|---|---|
| Rod Wong – Empty Rooms: Innovation in Biotech at RTW (Capital Allocators, EP. 310) | Apr 24, 2023 | 46m |